Suppliers and packagers for generic pharmaceutical drug: NABUMETONE

NABUMETONE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Chartwell Rx	NABUMETONE	nabumetone	TABLET;ORAL	075280	ANDA	Chartwell RX, LLC	62135-145-60	60 TABLET, FILM COATED in 1 BOTTLE (62135-145-60)	2002-02-25
Chartwell Rx	NABUMETONE	nabumetone	TABLET;ORAL	075280	ANDA	Chartwell RX, LLC	62135-146-60	60 TABLET, FILM COATED in 1 BOTTLE (62135-146-60)	2002-02-25
Invagen Pharms	NABUMETONE	nabumetone	TABLET;ORAL	078671	ANDA	PD-Rx Pharmaceuticals, Inc.	43063-972-20	20 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (43063-972-20)	2019-03-06
Invagen Pharms	NABUMETONE	nabumetone	TABLET;ORAL	078671	ANDA	PD-Rx Pharmaceuticals, Inc.	43063-972-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (43063-972-30)	2019-03-06

Nabumetone Drug Substance Suppliers: Market Landscape and Patent Analysis

Last updated: February 19, 2026

Nabumetone is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation associated with osteoarthritis and rheumatoid arthritis. Its active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA), is responsible for its therapeutic effects. The global market for nabumetone drug substance is supported by a defined set of suppliers, with patent exclusivity and manufacturing capabilities dictating market access and competition.

Key Players in Nabumetone Drug Substance Supply

The supply of nabumetone drug substance is concentrated among a limited number of manufacturers, reflecting the established nature of the drug and the technical requirements for its synthesis. These suppliers operate globally, serving both generic and branded pharmaceutical companies.

Major Manufacturers and Their Capabilities

Several entities have established themselves as significant producers of nabumetone drug substance. Their production capacity, quality control standards, and regulatory compliance are critical factors for pharmaceutical clients.

• Teva Pharmaceutical Industries Ltd.: As a major generic pharmaceutical company, Teva is a significant player in the API market, including nabumetone. Their global manufacturing footprint allows for large-scale production.
• Sun Pharmaceutical Industries Ltd.: Another leading global pharmaceutical company, Sun Pharma produces a wide range of APIs. Their involvement in nabumetone supply is a key component of the market.
• Mylan N.V. (now part of Viatris Inc.): Mylan historically supplied nabumetone API. The integration into Viatris may alter its specific role, but the underlying manufacturing capability remains.
• Alkem Laboratories Ltd.: This Indian pharmaceutical company is known for its API manufacturing and has been a supplier of nabumetone.
• Hetero Drugs Ltd.: A prominent Indian API manufacturer, Hetero Drugs is also involved in the production of nabumetone, contributing to market availability.
• Divi's Laboratories Limited: Known for its large-scale API production, Divi's is a potential supplier with significant manufacturing capacity.

These companies generally adhere to Good Manufacturing Practices (GMP) and possess regulatory approvals from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Geographic Distribution of Manufacturing

The manufacturing of nabumetone API is geographically dispersed, with a significant concentration in India and China, known for their robust API production infrastructure and cost-competitiveness. However, established players in North America and Europe also contribute to the supply chain, particularly for markets with stringent regulatory requirements.

• India: Dominant in global API production, Indian manufacturers leverage cost efficiencies and established expertise in complex organic synthesis.
• China: Another major hub for API manufacturing, Chinese suppliers offer competitive pricing and substantial production volumes.
• Europe and North America: While manufacturing costs can be higher, companies in these regions often focus on specialized APIs or cater to specific regional market demands, emphasizing compliance and supply chain security.

Nabumetone Patent Landscape

The patent landscape for nabumetone is largely characterized by expired composition of matter patents, allowing for widespread generic competition. However, process patents and formulation patents can still influence market dynamics and provide limited exclusivity.

Key Patent Expirations and Generic Entry

The original patents covering the composition of matter for nabumetone have long since expired. This has paved the way for numerous generic manufacturers to enter the market.

• Composition of Matter Patent Expiry: The foundational patents protecting nabumetone itself expired decades ago, enabling generic drug development and manufacturing. For example, U.S. Patent 3,644,598, related to the synthesis of arylalkanoic acids including nabumetone, was filed in 1970 and expired well before current market considerations.
• Generic Approvals: The U.S. FDA's Orange Book lists multiple generic versions of nabumetone, indicating the availability of bioequivalent products from various manufacturers. This signifies that the primary patent barriers have been overcome.

Existing and Emerging Process and Formulation Patents

While composition of matter patents are expired, innovation continues in the manufacturing processes and drug formulations. These patents can provide a competitive edge and limited market exclusivity.

• Process Patents: Companies may hold patents for novel or improved methods of synthesizing nabumetone or its key intermediate, 6-methoxy-2-naphthylacetic acid (6-MNA). These patents can cover specific reaction conditions, catalysts, or purification techniques that offer advantages in yield, purity, or cost. For instance, patents might describe more efficient routes to synthesize the precursor or enantioselective synthesis methods if specific isomers become therapeutically relevant or demonstrate improved profiles.
• Formulation Patents: Patents related to specific pharmaceutical formulations of nabumetone, such as extended-release tablets or improved dosage forms that enhance bioavailability or patient compliance, can also exist. These patents can offer a period of market exclusivity for a particular branded product or a specialized generic version.

Example of a Patent Strategy: A company might secure a patent for a novel crystallization process that yields nabumetone API with a specific particle size distribution, crucial for consistent dissolution rates in tablet formulations. This patent would not cover nabumetone itself but the method of producing a high-quality API for formulation.

Regulatory Considerations for Nabumetone Drug Substance

Manufacturing and supplying nabumetone drug substance requires strict adherence to global pharmaceutical regulations to ensure product quality, safety, and efficacy.

Good Manufacturing Practices (GMP) Compliance

All manufacturers of nabumetone API must comply with GMP regulations established by regulatory bodies worldwide.

• FDA (U.S. Food and Drug Administration): Manufacturers supplying to the U.S. market must adhere to 21 CFR Part 210 and 211, covering current GMP for finished pharmaceuticals. API manufacturers must also meet requirements outlined in ICH Q7, "Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients."
• EMA (European Medicines Agency): Compliance with EudraLex Volume 4, Part II (Basic Requirements for Active Substances used as Starting Materials), aligned with ICH Q7, is mandatory for the European Union market.
• Other Regulatory Bodies: Similar GMP standards are enforced by regulatory agencies in Japan (PMDA), Canada (Health Canada), and other major pharmaceutical markets.

Drug Master Files (DMFs) and Certificates of Suitability (CEPs)

Regulatory documentation is essential for the approval of nabumetone-containing drug products.

• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies like the FDA. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the DMF in their marketing applications without disclosing proprietary API information.
• Certificates of Suitability (CEPs): In Europe, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) demonstrates that an API complies with the monographs of the European Pharmacopoeia. A CEP is a key document for obtaining marketing authorization in European countries.

Impurity Profiling and Control

Controlling impurities in nabumetone API is a critical regulatory requirement.

• ICH Guidelines: International Council for Harmonisation (ICH) guidelines, such as ICH Q3A (R2) on impurities in new drug substances and ICH Q3C (R5) on residual solvents, provide a framework for identifying, qualifying, and controlling impurities.
• Specific Impurities: Manufacturers must identify and control process-related impurities, degradation products, and residual solvents to meet pharmacopoeial standards and regulatory limits. For nabumetone, potential impurities could arise from incomplete reactions, side reactions, or degradation of the molecule under certain storage or processing conditions. For example, residual starting materials or by-products from the synthesis of 6-methoxy-2-naphthylacetic acid would be critical to monitor.

Market Dynamics and Competitive Landscape

The nabumetone drug substance market is mature, characterized by intense competition among generic API manufacturers. Pricing, quality, and reliable supply are the primary competitive factors.

Pricing and Cost Competitiveness

The commoditized nature of nabumetone API, due to expired patents, leads to significant price pressure.

• Impact of Indian and Chinese Suppliers: Manufacturers in India and China often offer lower prices due to lower manufacturing costs, including labor and raw materials. This forces Western manufacturers to compete on niche markets, specialized quality, or established supply chain reliability.
• Volume-Based Pricing: Bulk purchases by large generic drug manufacturers typically secure lower per-kilogram pricing.

Quality and Regulatory Compliance as Differentiators

Despite price pressures, consistent high quality and robust regulatory compliance remain crucial for securing and maintaining supply contracts.

• Audits and Inspections: Pharmaceutical companies routinely audit their API suppliers to ensure compliance with GMP and quality standards. Unannounced inspections by regulatory bodies can also impact a supplier's standing.
• Supply Chain Security: Pharmaceutical companies increasingly prioritize supply chain resilience and transparency. Suppliers with a proven track record of reliable delivery and strong regulatory standing are preferred.

Future Outlook and Potential Disruptions

While the nabumetone market is stable, several factors could influence its future.

• New Therapeutic Applications: Discovery of new therapeutic uses for nabumetone or its metabolite, 6-MNA, could increase demand.
• Patent Litigation: While unlikely for the core composition of matter, patent litigation surrounding specific manufacturing processes or advanced formulations could arise, potentially creating temporary market shifts or requiring licensing agreements.
• Regulatory Scrutiny: Increased regulatory scrutiny on API quality, particularly regarding impurities or supply chain traceability, could lead to supplier consolidation or necessitate investment in advanced analytical capabilities.

Nabumetone Synthesis Overview

The synthesis of nabumetone (4-(6-methoxy-2-naphthyl)butan-2-one) typically involves the preparation of the key intermediate, 6-methoxy-2-naphthylacetic acid (6-MNA), followed by conversion to nabumetone.

Synthesis of 6-Methoxy-2-Naphthylacetic Acid (6-MNA)

Several synthetic routes exist for 6-MNA. A common approach involves:

1. Starting Material: 2-methoxynaphthalene.
2. Acylation: Friedel-Crafts acylation of 2-methoxynaphthalene with a suitable acylating agent (e.g., acetyl chloride or acetic anhydride) to introduce an acetyl group at the 6-position, yielding 6-methoxy-2-acetylnaphthalene.
3. Haloform Reaction (or similar oxidation): The acetyl group is then converted to a carboxyl group. A haloform reaction using a hypohalite (e.g., sodium hypochlorite or hypobromite) can cleave the methyl ketone to form the carboxylic acid, 6-methoxy-2-naphthoic acid.
4. Homologation: The carboxylic acid is then homologated to form the acetic acid derivative. This can be achieved through various methods, such as conversion to an acid halide, reaction with diazomethane followed by rearrangement, or reduction and subsequent oxidation. A common pathway involves reduction to the alcohol, conversion to a halide, and reaction with cyanide followed by hydrolysis to yield 6-MNA.

Conversion of 6-MNA to Nabumetone

Once 6-MNA is synthesized, it is converted to nabumetone. This typically involves a sequence of reactions to extend the carbon chain and introduce the ketone functionality.

1. Esterification: 6-MNA is often esterified to protect the carboxylic acid.
2. Reduction: The ester is reduced to the corresponding alcohol.
3. Halogenation: The alcohol is converted to a halide (e.g., bromide or chloride).
4. Coupling Reaction (e.g., Grignard or organolithium): The halide undergoes a coupling reaction with a suitable reagent to introduce the four-carbon chain. A common strategy involves reacting the halide with a reagent derived from acetoacetic ester or a similar precursor that can be later manipulated to form the methyl ketone. For example, reacting with the Grignard reagent derived from ethyl 4-bromobutanoate or a similar fragment.
5. Ketone Formation and Deprotection: Subsequent steps involve forming the methyl ketone and deprotecting functional groups as needed to arrive at nabumetone.

Note: Specific process patents may detail variations on these steps, optimizing for yield, purity, cost, or environmental impact.

Key Takeaways

• The nabumetone drug substance market is mature and competitive, dominated by established API manufacturers, primarily located in India and China.
• Expired composition of matter patents allow for broad generic competition.
• Key suppliers include Teva, Sun Pharma, Viatris (formerly Mylan), Alkem Laboratories, and Hetero Drugs.
• Regulatory compliance (GMP), quality control, and reliable supply are critical for API manufacturers.
• While process and formulation patents may exist, they offer limited market exclusivity compared to original composition patents.
• The synthesis of nabumetone involves multi-step organic chemistry, with the preparation of 6-methoxy-2-naphthylacetic acid (6-MNA) as a crucial intermediate.

FAQs

What are the main regulatory requirements for nabumetone API suppliers?

Suppliers must adhere to Good Manufacturing Practices (GMP) as defined by regulatory bodies like the FDA and EMA. They also need to provide detailed documentation through Drug Master Files (DMFs) or Certificates of Suitability (CEPs) and rigorously control impurities according to ICH guidelines.

How does patent expiry impact the nabumetone drug substance market?

The expiration of composition of matter patents for nabumetone has led to widespread generic entry, significantly increasing competition and driving down prices for the drug substance.

Which regions are the primary manufacturing hubs for nabumetone API?

India and China are the dominant manufacturing hubs for nabumetone API due to their cost-effective production capabilities and established pharmaceutical chemical industries.

What role do process patents play in the nabumetone market?

Process patents can offer limited exclusivity by protecting novel or improved methods of synthesizing nabumetone or its intermediates. These patents can provide a competitive advantage but do not block the sale of nabumetone itself once the primary patents have expired.

How do pharmaceutical companies assess and select nabumetone drug substance suppliers?

Pharmaceutical companies select suppliers based on a combination of factors including consistent API quality, adherence to regulatory standards, competitive pricing, reliable supply chain management, and the ability to pass rigorous audits and inspections.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations

[2] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/guidelines/guidelines-by-region

[3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from https://www.edqm.eu/en/certificates-suitability-cep

[4] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-regulations

[5] European Medicines Agency. (n.d.). EudraLex The Rules Governing Medicinal Products in the European Union. Volume 4 Good Manufacturing Practice. Retrieved from https://health.ec.europa.eu/medicinal-products/eudralex/volume-4_en

[6] U.S. Patent 3,644,598. (1972). Arylalkanoic acids. Retrieved from USPTO Patent Database. (Note: Specific access link may vary and require database search).